The oligonucleotide therapeutics market is growing, and the pipeline is diverse. With more than 1200 oligo therapeutics in development and over 20 commercialized oligonucleotide drugs on the market to date, the potential for these highly specific sequences is being realized and is set to continue. Building on 40 years of experience, we at Cytiva understand that achieving high-quality and cost-effective oligonucleotides for your patients depends on successful drug development, optimization to manufacture, and a smooth scale-up.
Having expertise and experience at hand is key when optimizing your synthesis process and will provide the right support for your full workflow process. When you collaborate with us to develop the system you need or purchase systems from Cytiva for your oligonucleotide workflow, you gain access to our network of oligonucleotide product specialists, scientists, and scientific support associates who can leverage their significant experience to fast-track your molecule’s development. In other words, we provide engineers and automation, assist you in optimization, and give you access to scientific support for your whole oligonucleotide manufacturing workflow. For all our systems, verification has already been done. Cytiva oligonucleotide synthesizers are tested and validated using our own workflow consumables in-house. This optimization can help you achieve better performance and improved yields with higher purity. Investing your time and making the right selections and decisions at the beginning of your journey can save you time later.
Use this brand-new eBook from Cytiva to learn more about the oligonucleotide market as a whole and about the full workflow solutions available today. We hope you enjoy it!
